Jazz Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell JAZZ and other ETFs, options, and stocks.About JAZZ
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio.
JAZZ Key Statistics
Stock Snapshot
The current Jazz Pharmaceuticals(JAZZ) stock price is $176.92, with a market capitalization of 10.75B. The stock trades at a price-to-earnings (P/E) ratio of -29.15.
As of 2025-11-27, Jazz Pharmaceuticals(JAZZ) stock has fluctuated between $176.66 and $181.61. The current price stands at $176.92, placing the stock +0.1% above today's low and -2.6% off the high.
The Jazz Pharmaceuticals(JAZZ)'s current trading volume is 905.17K, compared to an average daily volume of 2.18M.
During the past year, Jazz Pharmaceuticals(JAZZ) stock moved between $95.49 at its lowest and $182.99 at its peak.
During the past year, Jazz Pharmaceuticals(JAZZ) stock moved between $95.49 at its lowest and $182.99 at its peak.
JAZZ News
Jazz Pharmaceuticals recently announced positive top-line results from its Phase 3 HERIZON-GEA-01 trial, showing that Ziihera (zanidatamab-hrii) in combination...
Though JAZZ Pharmaceuticals JAZZ is not your typical marijuana stock, it is an unconventional player in this field. The company entered the cannabis space afte...
New insider activity at Jazz Pharmaceuticals ( (JAZZ) ) has taken place on November 24, 2025. TipRanks Black Friday Sale Claim 60% off TipRanks Premium for the...
Analyst ratings
84%
of 19 ratingsMore JAZZ News
UBS analyst Ashwani Verma downgraded Jazz Pharmaceuticals (JAZZ) to Neutral from Buy with a price target of $188, up from $163. Following the strong Phase 3 GEA...
Jazz Pharmaceuticals (JAZZ) released results from its Phase 3 HERIZON-GEA-01 trial, showing Ziihera combinations led to marked improvements in survival measures...